SIDE-BY-SIDE COMPARISON

CompareAitiavsCradle

Review features, pricing signals, strengths, and trade-offs before choosing.

Generated from current catalog profiles Catalog profile signals Use-case comparison
AI Drug Discovery & Protein/Molecule Design Software

Aitia

SF 7.2

Causal AI and disease digital twins

Contact sales
AI Drug Discovery & Protein/Molecule Design Software

Cradle

SF 7.5

AI protein design for wet labs

Contact sales

Quick decision guide

Choose based on your workflow

Aitia may fit better if...

  • Multi Omics
  • Lab Integration
  • Partner Workflows

Cradle may fit better if...

  • Target Discovery
  • Molecule Design
  • Protein Modeling

Overview

How each tool is described

Aitia

Aitia is an AI drug discovery company for pharma and research partners, using causal AI and disease digital twins to identify drug targets and biomarkers.

  1. Research focus: Its causal AI and computational biology approach supports R&D acceleration rather than guaranteed clinical outcomes, with candidates requiring downstream validation.
  2. Best-fit environment: Pharma and discovery research partners may benefit when disease digital twins fit target discovery and biomarker workflows.
  3. Engagement model: Access is partnership and research-led rather than self-service, making data access, collaboration structure, and timelines to validated leads key considerations.
  4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while collaboration costs should be assessed before longer programs.

Aitia is best evaluated through a focused pilot that tests one workflow, data requirements, and collaboration needs before broader commitment.

View full Aitia profile

Cradle

Cradle is an AI protein engineering platform for protein engineering and biotech teams, supporting the design and optimization of proteins for research programs.

  1. Research focus: It supports R&D acceleration and computational biology rather than guaranteed clinical outcomes, with candidates still requiring downstream validation and trials.
  2. Best-fit environment: Protein engineering and biotech teams may benefit most when accessible protein design fits established wet-lab workflows and in-house research programs.
  3. Engagement model: Access typically runs through pharma partnerships rather than self-service subscriptions, making collaboration structure, data requirements, and expected timelines to validated leads important buying considerations.
  4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, with value shaped by the depth of internal protein programs.

Cradle is best assessed as an accessible protein design layer whose fit depends on wet-lab integration, in-house expertise, and research objectives.

View full Cradle profile

Side-by-side

Key differences

Criteria
AI Drug Discovery & Protein/Molecule Design SoftwareAitia
AI Drug Discovery & Protein/Molecule Design SoftwareCradle
Best for
AI Drug Discovery & Protein/Molecule Design Software
AI Drug Discovery & Protein/Molecule Design Software
Score
7.2/10
7.5/10
Pricing
Contact sales
Contact sales
Category / audience
AI Healthcare & Medical Software › AI Drug Discovery & Protein/Molecule Design Software
AI Healthcare & Medical Software › AI Drug Discovery & Protein/Molecule Design Software

OVERLAP

Where Aitia and Cradle are similar

Both tools cover similar catalog signals. The deciding factor is usually workflow fit, implementation needs, and ecosystem fit.

3 capabilities5 workflows

Shared capabilities

Capability overlap

  • Knowledge GraphConnects biological and chemical knowledge sources
  • Virtual ScreeningScreens compound libraries against targets
  • Literature IntelligenceMines biomedical literature for relevant evidence

Shared workflows

Workflow overlap

  • Mine literature for research signalsMine biomedical literature for research and target signals.
  • Run virtual screens against targetsRun virtual screening across large compound libraries.
  • Collaborate with pharma partnersCollaborate with pharma partners on discovery programs.

Feature check

Side-by-side feature check

Feature
Aitia
Cradle
Multi OmicsIntegrates genomic and other omics data sources
-
Lab IntegrationConnects discovery insights with wet-lab workflows
-
Partner WorkflowsWorkflows for pharma partner collaborations
-
Target DiscoveryIdentifies potential drug targets from biological data
-
Molecule DesignGenerates and ranks small molecule candidates
-
Protein ModelingPredicts and designs protein structures
-
9 capabilities compared.6 differentiating rows are shown first.

The trade-offs

Pros & cons of each tool

Trade-offs

Aitia

Pros
  • Causal AI and disease digital twins
  • Built specifically for drug discovery teams, not bolt-on AI
  • Scales across organization-wide research programs
Cons
  • Engagement is partnership and research-led
Trade-offs

Cradle

Pros
  • Accessible protein design for wet labs
  • Concentrates on drug discovery depth over broad coverage
  • Scales to organization-wide healthcare rollouts
Cons
  • Best value needs in-house protein programs

Shared trade-offs

Catalog data lists these trade-offs for both tools.

Cons
  • Drug success still depends on downstream trials
  • Pricing is sales-led and needs scoping upfront

Final verdict

Best fit depends on your workflow

Catalog verdict · low confidence

Current catalog data shows meaningful overlap between Aitia and Cradle. Use the signals below to decide based on workflow, ecosystem, pricing, and implementation fit.

Shared catalog overlap

Aitia and Cradle share 8 catalog signals, so the decision should focus on fit rather than broad capability alone.

Differentiators available

Aitia has 4 visible decision signals and Cradle has 4.

Score signal

Cradle has the higher SoftFinders Score in the current catalog data.

TRY THEM YOURSELF

See which one fits your workflow

Both tools have their strengths, the best way to decide is to spend a few minutes inside each.